V. Bryan Lawlis's most recent trade in Geron Corp. was a trade of 180,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Geron Corp | V. Bryan Lawlis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| Geron Corp | V. Bryan Lawlis | Director | Purchase of securities on an exchange or from another person at price $ 1.18 per share. | 09 May 2025 | 13,300 | 13,300 (0%) | 0% | 1.2 | 15,667 | Common Stock |
| Geron Corp | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 35,000 | 0 | - | - | Stock Option (right to buy) | |
| Geron Corp | V. Bryan Lawlis | Director | Sale of securities on an exchange or to another person at price $ 3.75 per share. | 15 May 2024 | 35,000 | 0 (0%) | 0% | 3.8 | 131,250 | Common Stock |
| Geron Corp | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.94 per share. | 15 May 2024 | 35,000 | 35,000 (0%) | 0% | 1.9 | 67,900 | Common Stock |
| Geron Corp | V. Bryan Lawlis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 180,000 | 180,000 | - | - | Stock Option (right to buy) | |
| Geron Corp | V. Bryan Lawlis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 4,190 | 33,140 (0%) | 0% | 0 | Common Stock | |
| Geron Corp | V. Bryan Lawlis | Director | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 11 May 2023 | 35,000 | 0 (0%) | 0% | 3 | 105,000 | Common Stock |
| Geron Corp | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.10 per share. | 11 May 2023 | 35,000 | 35,000 (0%) | 0% | 1.1 | 38,500 | Common Stock |
| Geron Corp | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2023 | 35,000 | 0 | - | - | Stock Options (right to buy) | |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2023 | 8,500 | 0 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.81 per share. | 03 Apr 2023 | 8,500 | 37,450 (0%) | 0% | 67.8 | 576,385 | Common Stock |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Sale of securities on an exchange or to another person at price $ 97.09 per share. | 03 Apr 2023 | 8,500 | 28,950 (0%) | 0% | 97.1 | 825,265 | Common Stock |
| Aeglea BioTherapeutics Inc | V. Bryan Lawlis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 43,000 | 43,000 | - | - | Director Stock Option (right to buy) | |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 4,980 | 28,950 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Sale of securities on an exchange or to another person at price $ 83.66 per share. | 14 Apr 2022 | 4,250 | 23,970 (0%) | 0% | 83.7 | 355,555 | Common Stock |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.46 per share. | 14 Apr 2022 | 4,250 | 28,220 (0%) | 0% | 37.5 | 159,205 | Common Stock |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2022 | 4,250 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.46 per share. | 14 Jan 2022 | 4,250 | 28,220 (0%) | 0% | 37.5 | 159,205 | Common Stock |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Sale of securities on an exchange or to another person at price $ 87.61 per share. | 14 Jan 2022 | 4,250 | 23,970 (0%) | 0% | 87.6 | 372,343 | Common Stock |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 4,250 | 4,250 | - | - | Stock Option (Right to buy Common Stock) | |
| Aeglea BioTherapeutics Inc | V. Bryan Lawlis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 40,000 | 40,000 | - | - | Director Stock Option (right to buy) | |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 5,120 | 23,970 (0%) | 0% | 0 | Common Stock | |
| Geron Corp | V. Bryan Lawlis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Sale of securities on an exchange or to another person at price $ 76.90 per share. | 15 Apr 2021 | 7,500 | 18,850 (0%) | 0% | 76.9 | 576,750 | Common Stock |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2021 | 7,500 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 15 Apr 2021 | 7,500 | 26,350 (0%) | 0% | 26.5 | 198,675 | Common Stock |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 16 Feb 2021 | 7,500 | 26,350 (0%) | 0% | 26.5 | 198,675 | Common Stock |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 7,500 | 7,500 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical Inc | V. Bryan Lawlis | Director | Sale of securities on an exchange or to another person at price $ 87.41 per share. | 16 Feb 2021 | 7,500 | 18,850 (0%) | 0% | 87.4 | 655,575 | Common Stock |
| Coherus Biosciences Inc | V. Bryan Lawlis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |